ImmuPharma (LON:IMM) – CORP*: Appointment of Northland
Market Cap: £45.5m; Current Price: 37p
Appointment of Northland Capital Partners Ltd. as Joint Broker
ImmuPharma PLC announced the appointment of Northland Capital Partners as joint broker to the Company with immediate effect.
NORTHLAND CAPITAL PARTNERS VIEW: ImmuPharma is a late-clinical-stage drug development business. The company’s lead compound, Lupuzor, a potential treatment for Lupus, is undergoing a Phase 3 clinical trial, which is currently dosing patients across the US and Europe.